The administration announced that pharmaceutical companies agreed to reduce Medicare prices on 15 high-cost drugs—changes that could save taxpayers billions when they take effect in 2027.

Henrietta Treyz, Co-Founder at Veda Partners, weighs in on the implications of the Supreme Court’s upcoming ruling on presidential tariff authority, as the EU raises concerns over the expanding list of its products facing steep U.S. metal tariffs.

Henrietta Treyz, Co-Founder at Veda Partners, weighs in on the latest developments surrounding the U.S. government shutdown.

Henrietta Treyz, Co-Founder at Veda Partners, discussed the implications of renewed U.S.–China trade relations for American agriculture following the recent summit between Presidents Xi Jinping and Donald Trump.

President Trump announced that China will lift its boycott and resume purchasing millions of tons of American soybeans under a new trade truce between the two countries. The agreement offers a much-needed boost for U.S. farmers after months of uncertainty, though the final terms remain unclear.

The Trump administration’s push to lower U.S. drug prices through direct deals with major pharmaceutical companies — including Pfizer, AstraZeneca, and EMD Serono — has drawn scrutiny over its transparency and impact.

President Donald Trump announced a deal with AstraZeneca aimed at lowering drug costs through “Most Favored Nation” pricing — following a similar agreement with Pfizer. Both drugmakers agreed to sell select medications at discounted rates and join the new TrumpRx online platform, offering direct-to-consumer discounts.

Tom Keene highlights the Single Best Idea from the latest Bloomberg Surveillance Radio, featuring insights from Henrietta Treyz and Aakash Doshi.

With just weeks left before the government funding deadline, attention is shifting to how voters might assign blame if lawmakers fail to reach a deal.